Novartis' Cosentyx Goes Head-To-Head With Humira
Executive Summary
With the initiation of EXCEED and SURPASS, Novartis is aiming to challenge Humira’s status as the preferred first-line biologic for ankylosing spondylitis and psoriatic arthritis.
Topics
- Subjects
- Clinical Trials
- Biosimilars
- Research & Development
- Therapy Areas
- Immune Disorders
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GB001583
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
GB001583
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.